Poolbeg Pharma said partner OneThree Biotech has completed a tailored AI model of its Respiratory Syncytial Virus ('RSV') human challenge data enabling detailed analysis to get underway.
Results of this work are expected in the fourth quarter of 2022.
African Gold Group Inc said it has completed its name change to Toubani Resources Inc to better reflect its strategic focus on the development of the Kobada gold project in southern Mali.
Its shares began trading on the TSX Venture Exchange under a new ticker symbol 'TRE' at the opening of trading on June 15, 2022. The company said the name change also supported its move to dual list on the Australian Stock Exchange.
Arrow Exploration Corp (TSX-V:AXL, AIM:AXL, OTC:CSTPF) CEO Marshall Abbott has said the company is encouraged by the results of the Rio Cravo Sur-1 (RCS-1) well testing on the Tapir Block in the Llanos Basin of Colombia.
The RCS-1 well, which was spud on May 23, 2022, targeted a three-way fault bounded structure with multiple high-quality reservoir objectives on the Tapir Block in the Llanos Basin of Colombia. The well was drilled to a total measured depth of 8,656 feet (8,105 feet true vertical depth) and encountered six hydrocarbon-bearing intervals totaling 55 net feet of oil pay.
Genflow Biosciences PLC (LSE:GENF) said it has signed a research agreement with Magnitude Biosciences that will accelerate its future therapeutic developments and put it on track to carry out its research and pre-clinical drug discovery.
It said Magnitude provides an automated service using nematode worms to identify health-span extending drugs faster and more cost effectively than current approaches.
Mosman Oil and Gas Ltd (AIM:MSMN) told investors that net production in its third quarter, ending March 31, amounted to 11,756 barrels oil equivalent (22,409 boe gross).
It noted that final numbers for its fourth quarter are expected to be announced in late July and preliminary numbers for the first two months of the quarter totalled 15,682 boe (it noted that its measure of boe is based on calorific value rather than US dollar value).
Powerhouse Energy Group PLC (AIM:PHE, ETR:BT81) has appointed non-executive director Keith Riley as interim chair.
Riley is currently proprietor and chief executive officer of Vismundi Limited, a consultancy company providing services to the resources and waste management industry. Prior to that, between 1993 and 2012 he worked for Veolia Environmental Services PLC in a number of senior roles, including group managing director for technology.
88 Energy Ltd (AIM:88E, ASX:88E, OTC:EEENF) has agreed the acquisition of valuable exploration data for a key part of the Project Icewine acreage in Alaska.
The company, in a statement, told investors that a licensing agreement with SAExploration gives it the use of 3D seismic data for the Franklin Bluffs area which, significantly, covers parts of the SMD, SFS and BFF reservoir units which 88 Energy says are interpreted to extend from Pantheon Resources' (Pantheon) acreage onto Icewine.
ImmuPharma PLC (AIM:IMM, OTC:IMMPF) said its US partner has sought final regulatory guidance from the Food & Drug Administration (FDA) as it "actively prepares" for the start of the international phase III trial of Lupuzor, a potential treatment for the autoimmune disease lupus.
"This final step by Avion is a pivotal moment for the company and for the progress of Lupuzor towards becoming a ground-breaking new treatment for Lupus patients,” said ImmuPharma chief executive, Tim McCarthy.
NextEnergy Solar Fund Ltd (LSE:NESF) has seen its net asset value per share rise, driven by an increase in power price forecast assumptions.
The renewable energy investment company released its results for the year to 31 March 2022 in which it revealed net asset value (NAV) per share rose roughly 15% to 113.5p from 98.9p a year earlier.
ANGLE has published new research by the Swiss Federal Institute of Technology (ETH) suggesting the spread of breast cancer accelerates during sleep.
The study utilised ANGLE’s Parsortix system to investigate the impact of sleep on the release of circulating tumour cells (CTCs) in preclinical models and 30 patients with breast cancer (21 with early stage and 9 with metastatic disease).